Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019.

McLornan DP, Yakoub-Agha I, Robin M, Chalandon Y, Harrison CN, Kroger N.

Haematologica. 2019 Mar 14. pii: haematol.2018.206151. doi: 10.3324/haematol.2018.206151. [Epub ahead of print]

2.

Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis.

Robin M, de Wreede LC, Wolschke C, Schetelig J, Eikema DJ, Van Lint MT, Knelange NS, Beelen D, Brecht A, Niederwieser D, Vitek A, Bethge W, Arnold R, Finke J, Volin L, Yakoub-Agha I, Nagler A, Poiré X, Einsele H, Chevallier P, Holler E, Ljungman P, Robinson S, Radujkovic A, McLornan D, Chalandon Y, Kröger N.

Haematologica. 2019 Feb 7. pii: haematol.2018.205211. doi: 10.3324/haematol.2018.205211. [Epub ahead of print]

3.

Antilymphocyte Globulin for matched sibling donor transplantation in patients with myelofibrosis.

Robin M, Chevret S, Koster L, Wolschke C, Yakoub-Agha I, Bourhis JH, Chevallier P, Cornelissen JJ, Reményi P, Maertens J, Poiré X, Craddock C, Socié G, Itälä-Remes M, Schouten HC, Marchand T, Passweg J, Blaise D, Damaj G, Ozkurt ZN, Zuckerman T, Cluzeau T, Labussière-Wallet H, Cammenga J, McLornan D, Chalandon Y, Kröger N.

Haematologica. 2019 Jan 17. pii: haematol.2018.201400. doi: 10.3324/haematol.2018.201400. [Epub ahead of print]

4.

A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline.

McMullin MF, Harrison CN, Ali S, Cargo C, Chen F, Ewing J, Garg M, Godfrey A, S SK, McLornan DP, Nangalia J, Sekhar M, Wadelin F, Mead AJ; BSH Committee.

Br J Haematol. 2019 Jan;184(2):176-191. doi: 10.1111/bjh.15648. Epub 2018 Nov 27. No abstract available.

PMID:
30478826
5.

A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis: A British Society for Haematology Guideline.

McMullin MFF, Mead AJ, Ali S, Cargo C, Chen F, Ewing J, Garg M, Godfrey A, Knapper S, McLornan DP, Nangalia J, Sekhar M, Wadelin F, Harrison CN; British Society for Haematology Guideline.

Br J Haematol. 2019 Jan;184(2):161-175. doi: 10.1111/bjh.15647. Epub 2018 Nov 13. No abstract available.

PMID:
30426472
6.

Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation.

Raj K, Eikema DJ, McLornan DP, Olavarria E, Blok HJ, Bregante S, Ciceri F, Passweg J, Ljungman P, Schaap N, Carlson K, Zuckerman T, de Wreede LC, Volin L, Koc Y, Diez-Martin JL, Brossart P, Wolf D, Blaise D, Bartolomeo PD, Vitek A, Robin M, Yakoub-Agha I, Chalandon Y, Kroger N.

Biol Blood Marrow Transplant. 2018 Nov 5. pii: S1083-8791(18)30650-5. doi: 10.1016/j.bbmt.2018.10.017. [Epub ahead of print]

PMID:
30408564
7.

Diagnostic algorithm for lower-risk myelodysplastic syndromes.

Mufti GJ, McLornan DP, van de Loosdrecht AA, Germing U, Hasserjian RP.

Leukemia. 2018 Aug;32(8):1679-1696. doi: 10.1038/s41375-018-0173-2. Epub 2018 Jun 26. Review.

PMID:
29946191
8.

Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT.

McLornan DP, Szydlo R, Robin M, van Biezen A, Koster L, Blok HJP, Van Lint MT, Finke J, Vitek A, Carlson K, Griskevicius L, Holler E, Itälä-Remes M, Schaap M, Socié G, Bay JO, Beguin Y, Bruno B, Cornelissen JJ, Gedde-Dahl T, Ljungman P, Rubio MT, Yakoub-Agha I, Klyuchnikov E, Olavarria E, Chalandon Y, Kröger N.

Br J Haematol. 2018 Aug;182(3):418-422. doi: 10.1111/bjh.15407. Epub 2018 May 29.

9.

GATA2 monoallelic expression underlies reduced penetrance in inherited GATA2-mutated MDS/AML.

Al Seraihi AF, Rio-Machin A, Tawana K, Bödör C, Wang J, Nagano A, Heward JA, Iqbal S, Best S, Lea N, McLornan D, Kozyra EJ, Wlodarski MW, Niemeyer CM, Scott H, Hahn C, Ellison A, Tummala H, Cardoso SR, Vulliamy T, Dokal I, Butler T, Smith M, Cavenagh J, Fitzgibbon J.

Leukemia. 2018 Nov;32(11):2502-2507. doi: 10.1038/s41375-018-0134-9. Epub 2018 Apr 19. No abstract available.

10.

Alemtuzumab vs anti-thymocyte globulin in patients transplanted from an unrelated donor after a reduced intensity conditioning.

Robin M, Raj K, Chevret S, Gauthier J, de Lavallade H, Michonneau D, McLornan D, Peffault de Latour R, Potter V, Kulasekararaj A, Sicre de Fontbrune F, Pagliuca A, Yakoub-Agha I, Socié G, Mufti GJ.

Eur J Haematol. 2018 Oct;101(4):466-474. doi: 10.1111/ejh.13085.

PMID:
29714032
11.

Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.

Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R.

Nat Med. 2018 Apr 10;24(4):526. doi: 10.1038/nm0418-526c.

PMID:
29634689
12.

Anti-type M phospholipase A2 receptor antibody-positive membranous nephropathy as a part of multi-system autoimmune syndrome post-allogeneic stem cell transplantation.

Tedjaseputra A, McLornan D, McCormick J, Raj K, de Lavallade H, Potter V, Kenyon M, Pagliuca A, Marsh J, Mufti G.

Intern Med J. 2018 Apr;48(4):481-483. doi: 10.1111/imj.13762. No abstract available.

PMID:
29623981
13.

Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.

Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R.

Nat Med. 2018 Mar;24(3):282-291. doi: 10.1038/nm.4484. Epub 2018 Feb 12. Erratum in: Nat Med. 2018 Apr 10;24(4):526.

14.

Heterozygous RTEL1 variants in bone marrow failure and myeloid neoplasms.

Marsh JCW, Gutierrez-Rodrigues F, Cooper J, Jiang J, Gandhi S, Kajigaya S, Feng X, Ibanez MDPF, Donaires FS, Lopes da Silva JP, Li Z, Das S, Ibanez M, Smith AE, Lea N, Best S, Ireland R, Kulasekararaj AG, McLornan DP, Pagliuca A, Callebaut I, Young NS, Calado RT, Townsley DM, Mufti GJ.

Blood Adv. 2018 Jan 4;2(1):36-48. doi: 10.1182/bloodadvances.2017008110. eCollection 2018 Jan 9.

15.

Current treatment algorithm for the management of patients with myelofibrosis, JAK inhibitors, and beyond.

Harrison CN, McLornan DP.

Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):489-497. doi: 10.1182/asheducation-2017.1.489. Review.

16.

Shortened telomeres in essential thrombocythemia: clinicopathological and treatment correlations.

Alimam S, McLornan DP, Jiang J, Radia D, Mufti GJ, Harrison CN.

Haematologica. 2018 Jun;103(6):e234-e236. doi: 10.3324/haematol.2017.180851. Epub 2017 Nov 30. No abstract available.

17.

SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.

Mesa RA, Kiladjian JJ, Catalano JV, Devos T, Egyed M, Hellmann A, McLornan D, Shimoda K, Winton EF, Deng W, Dubowy RL, Maltzman JD, Cervantes F, Gotlib J.

J Clin Oncol. 2017 Dec 1;35(34):3844-3850. doi: 10.1200/JCO.2017.73.4418. Epub 2017 Sep 20.

PMID:
28930494
18.

Managing side effects of JAK inhibitors for myelofibrosis in clinical practice.

Saeed I, McLornan D, Harrison CN.

Expert Rev Hematol. 2017 Jul;10(7):617-625. doi: 10.1080/17474086.2017.1337507. Epub 2017 Jun 19. Review.

PMID:
28571503
19.

Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia.

Gunawan AS, McLornan DP, Wilkins B, Waghorn K, Hoade Y, Cross NCP, Harrison CN.

Haematologica. 2017 Jun;102(6):e238-e240. doi: 10.3324/haematol.2017.163790. Epub 2017 Mar 16. No abstract available.

20.

Guideline for the investigation and management of eosinophilia.

Butt NM, Lambert J, Ali S, Beer PA, Cross NC, Duncombe A, Ewing J, Harrison CN, Knapper S, McLornan D, Mead AJ, Radia D, Bain BJ; British Committee for Standards in Haematology.

Br J Haematol. 2017 Feb;176(4):553-572. doi: 10.1111/bjh.14488. Epub 2017 Jan 23. No abstract available.

21.

RPL27A is a target of miR-595 and may contribute to the myelodysplastic phenotype through ribosomal dysgenesis.

Alkhatabi HA, McLornan DP, Kulasekararaj AG, Malik F, Seidl T, Darling D, Gaken J, Mufti GJ.

Oncotarget. 2016 Jul 26;7(30):47875-47890. doi: 10.18632/oncotarget.10293.

22.

Disease characteristics and outcomes in younger adults with primary and secondary myelofibrosis.

Beauverd Y, Alimam S, McLornan DP, Radia DH, Harrison CN.

Br J Haematol. 2016 Oct;175(1):37-42. doi: 10.1111/bjh.14173. Epub 2016 Jun 13.

PMID:
27293069
23.

Deep phenotyping of Tregs identifies an immune signature for idiopathic aplastic anemia and predicts response to treatment.

Kordasti S, Costantini B, Seidl T, Perez Abellan P, Martinez Llordella M, McLornan D, Diggins KE, Kulasekararaj A, Benfatto C, Feng X, Smith A, Mian SA, Melchiotti R, de Rinaldis E, Ellis R, Petrov N, Povoleri GA, Chung SS, Thomas NS, Farzaneh F, Irish JM, Heck S, Young NS, Marsh JC, Mufti GJ.

Blood. 2016 Sep 1;128(9):1193-205. doi: 10.1182/blood-2016-03-703702. Epub 2016 Jun 8.

24.

Safety considerations when treating myelofibrosis.

O'Sullivan JM, McLornan DP, Harrison CN.

Expert Opin Drug Saf. 2016 Sep;15(9):1185-92. doi: 10.1080/14740338.2016.1185414. Epub 2016 Jun 1. Review.

PMID:
27187785
25.

Thiamine deficiency appears uncommon in patients with Myeloproliferative Neoplasms.

Curto-García N, Harrison CN, McLornan DP, Radia DH.

Br J Haematol. 2017 Jul;178(2):338-340. doi: 10.1111/bjh.14128. Epub 2016 May 2. No abstract available.

PMID:
27135305
26.

Mutations in histone modulators are associated with prolonged survival during azacitidine therapy.

Tobiasson M, McLornan DP, Karimi M, Dimitriou M, Jansson M, Ben Azenkoud A, Jädersten M, Lindberg G, Abdulkadir H, Kulasekararaj A, Ungerstedt J, Lennartsson A, Ekwall K, Mufti GJ, Hellström-Lindberg E.

Oncotarget. 2016 Apr 19;7(16):22103-15. doi: 10.18632/oncotarget.7899.

27.

Beneficial effects of JAK inhibitor therapy in Systemic Mastocytosis.

Dowse R, Ibrahim M, McLornan DP, Moonim MT, Harrison CN, Radia DH.

Br J Haematol. 2017 Jan;176(2):324-327. doi: 10.1111/bjh.13951. Epub 2016 Feb 5. No abstract available.

PMID:
26847591
28.

Ruxolitinib: evolution or revolution in treatment of patients with polycythemia vera?

Beauverd Y, McLornan DP, Radia DH, Harrison CN.

Future Oncol. 2016 Mar;12(6):739-49. doi: 10.2217/fon-2015-0023. Epub 2016 Feb 5. Review.

PMID:
26846873
29.

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.

Shanavas M, Popat U, Michaelis LC, Fauble V, McLornan D, Klisovic R, Mascarenhas J, Tamari R, Arcasoy MO, Davies J, Gergis U, Ukaegbu OC, Kamble RT, Storring JM, Majhail NS, Romee R, Verstovsek S, Pagliuca A, Vasu S, Ernst B, Atenafu EG, Hanif A, Champlin R, Hari P, Gupta V.

Biol Blood Marrow Transplant. 2016 Mar;22(3):432-40. doi: 10.1016/j.bbmt.2015.10.005. Epub 2015 Oct 19.

30.

Pacritinib: a new agent for the management of myelofibrosis?

Beauverd Y, McLornan DP, Harrison CN.

Expert Opin Pharmacother. 2015;16(15):2381-90. doi: 10.1517/14656566.2015.1088831. Review.

PMID:
26389774
31.

The use of JAK inhibitors for low-risk myelofibrosis.

Alimam S, McLornan D, Harrison C.

Expert Rev Hematol. 2015 Oct;8(5):551-3. doi: 10.1586/17474086.2015.1074858. Epub 2015 Aug 6.

PMID:
26343888
32.

How We Treat Myeloproliferative Neoplasms.

Harrison CN, McLornan DP, Francis YA, Woodley C, Provis L, Radia DH.

Clin Lymphoma Myeloma Leuk. 2015 Jun;15 Suppl:S19-26. doi: 10.1016/j.clml.2015.02.032.

PMID:
26297273
33.

Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group.

Kröger NM, Deeg JH, Olavarria E, Niederwieser D, Bacigalupo A, Barbui T, Rambaldi A, Mesa R, Tefferi A, Griesshammer M, Gupta V, Harrison C, Alchalby H, Vannucchi AM, Cervantes F, Robin M, Ditschkowski M, Fauble V, McLornan D, Ballen K, Popat UR, Passamonti F, Rondelli D, Barosi G.

Leukemia. 2015 Nov;29(11):2126-33. doi: 10.1038/leu.2015.233. Epub 2015 Aug 21. Review.

PMID:
26293647
34.

Immunological Consequences of JAK Inhibition: Friend or Foe?

McLornan DP, Khan AA, Harrison CN.

Curr Hematol Malig Rep. 2015 Dec;10(4):370-9. doi: 10.1007/s11899-015-0284-z. Review.

PMID:
26292803
35.

The effects of JAK inhibitor therapy upon novel markers of thrombosis In myeloproliferative neoplasms.

Keohane C, McLornan DP, Sanchez K, Connor C, Radia D, Harrison CN.

Haematologica. 2015 Sep;100(9):e348-50. doi: 10.3324/haematol.2015.128918. Epub 2015 Jun 18. No abstract available.

36.

JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells.

Keohane C, Kordasti S, Seidl T, Perez Abellan P, Thomas NS, Harrison CN, McLornan DP, Mufti GJ.

Br J Haematol. 2015 Oct;171(1):60-73. doi: 10.1111/bjh.13519. Epub 2015 Jun 15.

PMID:
26075866
37.

Targeting of the Hedgehog pathway in myeloid malignancies: still a worthy chase?

Khan AA, Harrison CN, McLornan DP.

Br J Haematol. 2015 Aug;170(3):323-35. doi: 10.1111/bjh.13426. Epub 2015 Apr 19. Review.

PMID:
25892100
38.

Applying synthetic lethality for the selective targeting of cancer.

McLornan DP, List A, Mufti GJ.

N Engl J Med. 2014 Oct 30;371(18):1725-35. doi: 10.1056/NEJMra1407390. Review. No abstract available.

PMID:
25354106
39.

Autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: analysis of 533 adult patients who underwent transplantation at King's College Hospital.

Wang M, Wang W, Abeywardane A, Adikarama M, McLornan D, Raj K, de Lavallade H, Devereux S, Mufti GJ, Pagliuca A, Potter VT, Mijovic A.

Biol Blood Marrow Transplant. 2015 Jan;21(1):60-6. doi: 10.1016/j.bbmt.2014.09.009. Epub 2014 Sep 28.

40.

Combination therapy with ruxolitinib plus 5-azacytidine or continuous infusion of low dose cytarabine is feasible in patients with blast-phase myeloproliferative neoplasms.

Mwirigi A, Galli S, Keohane C, Raj K, Radia DH, Harrison CN, McLornan DP.

Br J Haematol. 2014 Dec;167(5):714-6. doi: 10.1111/bjh.13046. Epub 2014 Jul 22. No abstract available.

PMID:
25048366
41.

Nonmyeloablative peripheral blood haploidentical stem cell transplantation for refractory severe aplastic anemia.

Clay J, Kulasekararaj AG, Potter V, Grimaldi F, McLornan D, Raj K, de Lavallade H, Kenyon M, Pagliuca A, Mufti GJ, Marsh JC.

Biol Blood Marrow Transplant. 2014 Nov;20(11):1711-6. doi: 10.1016/j.bbmt.2014.06.028. Epub 2014 Jul 10.

42.

Safety evaluation of ruxolitinib for treating myelofibrosis.

Galli S, McLornan D, Harrison C.

Expert Opin Drug Saf. 2014 Jul;13(7):967-76. doi: 10.1517/14740338.2014.916273. Epub 2014 Jun 4. Review.

PMID:
24896661
43.

Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning.

Raj K, Pagliuca A, Bradstock K, Noriega V, Potter V, Streetly M, McLornan D, Kazmi M, Marsh J, Kwan J, Huang G, Getzendaner L, Lee S, Guthrie KA, Mufti GJ, O'Donnell P.

Biol Blood Marrow Transplant. 2014 Jun;20(6):890-5. doi: 10.1016/j.bbmt.2014.03.003. Epub 2014 Mar 18.

44.

Myelofibrosis.

Harrison C, McLornan D.

Hematology. 2014 Mar;19(2):120-1. doi: 10.1179/1024533213Z.000000000257. No abstract available.

PMID:
24611775
45.

Combination therapies in Myeloproliferative Neoplasms: why do we need them and how to identify potential winners?

McLornan D, Harrison C.

J Cell Mol Med. 2013 Nov;17(11):1410-4. doi: 10.1111/jcmm.12202. No abstract available.

46.

Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study.

Jovanovic JV, Ivey A, Vannucchi AM, Lippert E, Oppliger Leibundgut E, Cassinat B, Pallisgaard N, Maroc N, Hermouet S, Nickless G, Guglielmelli P, van der Reijden BA, Jansen JH, Alpermann T, Schnittger S, Bench A, Tobal K, Wilkins B, Cuthill K, McLornan D, Yeoman K, Akiki S, Bryon J, Jeffries S, Jones A, Percy MJ, Schwemmers S, Gruender A, Kelley TW, Reading S, Pancrazzi A, McMullin MF, Pahl HL, Cross NC, Harrison CN, Prchal JT, Chomienne C, Kiladjian JJ, Barbui T, Grimwade D.

Leukemia. 2013 Oct;27(10):2032-9. doi: 10.1038/leu.2013.219. Epub 2013 Jul 17.

47.

Prognostic and therapeutic relevance of c-FLIP in acute myeloid leukaemia.

McLornan D, Hay J, McLaughlin K, Holohan C, Burnett AK, Hills RK, Johnston PG, Mills KI, McMullin MF, Longley DB, Gilkes A.

Br J Haematol. 2013 Jan;160(2):188-98. doi: 10.1111/bjh.12108. Epub 2012 Nov 20. Erratum in: Br J Haematol. 2013 Aug;162(3):428. Gilkes, Amanda [added].

PMID:
23167276
48.

Pneumonitis post-haematopoeitic stem cell transplant - cytopathology clinches diagnosis.

Yapa HM, McLornan DP, Raj K, Streetly M, Kazmi M, Cuthill K, Laurie J, Menon PA, Macmahon E.

J Clin Virol. 2012 Nov;55(3):278-81. doi: 10.1016/j.jcv.2012.08.007. Epub 2012 Sep 6.

PMID:
22959064
49.

Allogeneic stem cell transplantation for myelofibrosis in 2012.

McLornan DP, Mead AJ, Jackson G, Harrison CN.

Br J Haematol. 2012 May;157(4):413-25. doi: 10.1111/j.1365-2141.2012.09107.x. Epub 2012 Mar 29. Review.

PMID:
22463701
50.

Prognostic significance of TRAIL signaling molecules in stage II and III colorectal cancer.

McLornan DP, Barrett HL, Cummins R, McDermott U, McDowell C, Conlon SJ, Coyle VM, Van Schaeybroeck S, Wilson R, Kay EW, Longley DB, Johnston PG.

Clin Cancer Res. 2010 Jul 1;16(13):3442-51. doi: 10.1158/1078-0432.CCR-10-0052. Epub 2010 Jun 22.

Supplemental Content

Loading ...
Support Center